(Press-News.org) ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes a link between positive antiphospholipid antibodies and an increased risk of future cardiovascular disease in patients with systemic lupus erythematosus (SLE) (Abstract #0552).
Antiphospholipid antibodies (aPLs) are autoantibodies directed against phospholipid-binding proteins. In antiphospholipid syndrome, they are associated with heart attack, stroke, and pulmonary embolism, and with miscarriage and stillbirth during pregnancy.
People with SLE also have a greatly increased risk of cardiovascular disease (CVD), a major cause of morbidity and mortality in these patients. About 30 to 40% have aPLs, yet little is known about how the antibodies affect CVD risk. Suspecting they might play a pivotal role, Yufang Ding, a medical student at Peking Union Medical College Hospital, Beijing, China, and her mentors, Mengtao Li and Jiuliang Zhao, decided to explore the association between aPLs and future atherosclerotic cardiovascular disease in SLE.
For their multi-center prospective study, the researchers recruited more than 1,500 patients diagnosed with lupus between 2006 and 2021 through the Chinese SLE Treatment and Research Group (CSTAR), the largest lupus registry in China. More than 90%were women, and all were East Asian.
The team measured seven aPL isotopes at diagnosis and during follow-up:
Anticardiolipin (aCL) antibodies
IgG
IgM
IgA
Anti-beta-2-glycoprotein I (aβ2GPI) antibodies
IgG
IgM
IgA
Lupus anticoagulant (LA), a misnomer since aPLs increase the chance of blood clots
Of included patients, 525 (33.4%) had positive aPLs. Lupus anticoagulant was the most prevalent (20.6%) followed by aCL IgG (15.8%. One hundred sixteen patients (7.37%), of whom 92 were aPL positive, developed atherosclerotic cardiovascular disease (ASCVD) during a roughly 4.5-year follow-up. Atherosclerotic cardiovascular disease was defined as a new nonfatal heart attack, nonfatal stroke, coronary or peripheral artery revascularization or cardiovascular death.
The team also conducted three analyses. The analysis concluded, first, that both aPL positivity and traditional risk factors were associated with atherosclerotic cardiovascular disease. Second, aCL IgG, aCL IgM and lupus anticoagulant were independently associated with atherosclerotic cardiovascular disease, along with smoking, hypertension and patient gender and age. Lastly, third, anticoagulant and antiplatelet therapy can reduce atherosclerotic cardiovascular disease risk in SLE patients.
Ding, the study’s lead author, says previous research has shown that an inflammatory cascade is triggered when aPLs bind to β2GPI, leading to inflammation, vasculopathy, and thrombosis, so the positive correlation between aPLs, traditional risk factors and ASCVD was expected.
But, Ding notes, “Few studies have demonstrated the role of different aPL isotopes in ACSD development. In our study, we identified that aCL IgG, aCL IgM and lupus anticoagulant positivity are independently associated with ASCVD after adjusting for traditional cardiovascular disease risk factors.”
The study has a few limitations. One, Ding says, is the “dynamic and time-varying interplay among aPL positivity,” which makes statistical analysis challenging. And because this is an observational study, it is hard to account for confounding factors like treatment choices and outcomes.
Still, Ding thinks the study results suggest that at the least, lupus patients should be tested for aPLs and those who are aPL-positive should undergo more careful surveillance for future heart disease. And, he says, “The use of low-dose aspirin for primary thrombosis prevention should be carefully considered in SLE patients with positive anticardiolipin antibodies or lupus anticoagulant. We are also looking forward to discussing the prevention role of the Mediterranean diet and exercise through an intervention study in the future.”
This work was supported by the Chinese National Key Research R&D Program and the CAMS Innovation fund for Medical Sciences.
###
About ACR Convergence
ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 240 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit https://rheumatology.org/annual-meeting, or join the conversation on Twitter by following the official hashtag (#ACR23).
About the American College of Rheumatology
Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit www.rheumatology.org.
END
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies (Abstract #L03).
VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in the UBA1 gene. It is marked by widespread inflammation leading to a range of symptoms that affect the skin, lungs, blood vessels and joints. The name is an acronym for disease characteristics: vacuoles in bone marrow, E1 enzyme (the enzyme encoded by the UBA1 gene), ...
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes the expansion of a novel program to train primary care physicians (PCPs) in the diagnosis and management of rheumatoid arthritis (RA) in Native American communities that have little or no access to rheumatology care (Abstract #2455).
Despite the high prevalence of RA and other rheumatologic diseases among Native Americans, many Native American communities lack adequate access to subspecialized care. As a result, responsibility for treatment has shifted to primary care providers, who often do not feel confident prescribing RA medications or ...
ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477).
Tumor necrosis factor (TNF) inhibitors such as adalimumab and infliximab are often prescribed for inflammatory forms of arthritis that have not improved with other treatments. Although studies suggest the drugs are safe during pregnancy, ...
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, reports the incidence and risk factors for new-onset interstitial lung disease (ILD) in previously ILD-negative systemic sclerosis patients (Abstract #1700).
Interstitial lung disease is a common complication and cause of death in systemic sclerosis (SSc, scleroderma). Although the prevalence and risk factors for ILD are well known, less is known about the annual incidence and risk factors associated with the disease that occurs in patients who test negative on screening tests conducted at baseline. To answer these questions, Liubov Petelytska, ...
In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases. The findings, published in the Journal of Clinical Investigation and led by scientists at the National Institute of Neurological Disorders and Stroke (NINDS), part of NIH, may advance efforts to detect the earliest changes that years later lead to Parkinson’s disease and Lewy body dementia.
In ...
Macarena de la Fuente, MD, chief of neuro-oncology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been elected to the Society of Neuro-Oncology (SNO)’s board of directors.
She will serve as the neurology representative and becomes the first Hispanic elected to the multidisciplinary board, which strives to advance brain tumor research, education and collaboration.
De la Fuente has been an SNO member for over a decade and previously served as chair of the society’s ...
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines (Abstract #0607).
Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease marked by the production of autoantibodies to nucleic acid DNA and nuclear protein autoantigens and is associated with dysfunctional B cells. It mainly affects women and is more common and severe in people who ...
PLYMOUTH MEETING, PA [November 7, 2023] — New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy. According to an analysis of 1,191 patients with early-stage breast cancer—using data collected in the SWOG S0221 study—20.7% of patients with vitamin D deficiency experienced at least a grade 3 level of chemotherapy-induced peripheral neuropathy (CIPN), compared to 14.2% of those with sufficient vitamin D levels. The researchers ...
The rapid adoption of zero-emission electric vehicles will move the nation close to an 80% or more drop in transportation greenhouse gas emissions by 2050 from the 2019 level according to researchers from the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL).
The researchers came to that conclusion after running thousands of computer simulations on the steps needed to decarbonize passenger and freight travel, which make up the largest contributor to greenhouse gases. While they advised that “no single technology, policy, or behavioral change” is enough by itself to reach the target, eliminating tailpipe emissions would be a major factor.
“There ...
After the Southwest Research Institute-led Lucy mission flew past the asteroid Dinkinesh, the team discovered that it is even more “marvelous” as its newly discovered satellite is now shown to be a double-lobed moonlet. As NASA’s Lucy spacecraft continued to return data acquired during its first asteroid encounter on Nov. 1, 2023, the team discovered that Dinkinesh’s surprise satellite is itself a contact binary, made of two smaller objects touching each other.
In the first image of Dinkinesh and its satellite taken at closest approach, the two lobes of the contact binary lined up, one behind the other, ...
